Anlotinib in Sarcoma, Version 2.1 15-October-2019

• Research type

  Research Study

• Full title

  A Phase III Study of AL3818 (Catequentinib, Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

• IRAS ID

  277255

• Contact name

  Robin Jones

• Contact email

  Robin.Jones@rmh.nhs.uk

• Sponsor organisation

  Advenchen Laboratories LLC

• Eudract number

  2017-001655-31

• Clinicaltrials.gov Identifier

  NCT03016819

• Duration of Study in the UK

  4 years, 0 months, 1 days

• Research summary

  This is a phase 3 study looking to explore safety and efficacy of the study drug, Anlotinib (AL3818), in patients with rare types of metastatic sarcomas (sarcoma are affecting blood vessels, bones and organs connecting tissues)

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  20/LO/0351

• Date of REC Opinion

  29 Apr 2020

• REC opinion

  Further Information Favourable Opinion